Title : Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Pub. Date : 2017 Nov 30

PMID : 29018077






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-XL and MCL-1. venetoclax MCL1 apoptosis regulator, BCL2 family member Homo sapiens